Business
ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
-- U.S. Food & Drug Administration (FDA) approves TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- --
About this update from Chemocentryx Inc.
[{"type":"text","content":"-- U.S. Food & Drug Administration (FDA) approves TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- -- TAVNEOS approved also in Japan; European CHMP opinion expected this month -- -- Pipeline advances: Company intends to meet with FDA on path for TAVNEOS in C3 Glomerulopathy (C3G) and Hidradenitis Suppurativa (HS); plans to initiate clinical development of TAVNEOS in Lupus Nephritis (LN) in 2022 -- -- Clinical development underway of next generation orally-administered immune checkpoint inhibitor CCX559 -- -- $372 million in cash and investments at September 30, 2021 -- -- Conference call today at 5:00 p.m. Eastern Time -- SAN CARLOS, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced financial results for the third quarter ended September 30, 2021 and provided an overview of recent corporate highlights. “TAVNEOS is approved and now launched in the U.S.,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “With these events, we have begun at last to achieve two of our most foundational aspirations: first, to improve the lives of patients’ who endure with severe disease, and second, to become an integrated biopharmaceutical company which has discovered, developed, and now markets a drug of its own creation. We hope too that the approval of TAVNEOS marks only the beginning of our promise to people living with major unmet medical needs. Our intent is to proceed now with discussions with regulators on how best to move forward TAVNEOS programs in C3G and HS, and we plan to initiate clinical development of TAVNEOS in lupus nephritis this coming year as well. Let’s also remember that our orally administered checkpoint inhibitor CCX559 is now in development for the treatment of cancer. I like to think we have important goals for patients, and a pipeline to match.” Key Highlights and Recent Developments In October the Company announced FDA approval of TAVNEOS (avacopan) as an adjunctive treatment in adult patients with severe active ANCA-associated vasculitis (or ANCA vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms of ANCA vasculitis), in combination with standard therapy. TAVNEOS is the first orally-administered inhibitor of the compleme...